<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1002</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2020-16-3-153-164</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">High-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. From total to focal ablation</article-title><trans-title-group xml:lang="ru"><trans-title>Высокоинтенсивный сфокусированный ультразвук (HIFU) в лечении локализованных форм рака предстательной железы. От тотальной к фокальной аблации</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aboyan</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Абоян</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>344011 Ростов-на-Дону, переулок Доломановский, 70 / 3.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pakus</surname><given-names>S. M.</given-names></name><name xml:lang="ru"><surname>Пакус</surname><given-names>С. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>Пакус Сергей Михайлович.344011 Ростов-на-Дону, переулок Доломановский, 70 / 3.</p></bio><email>sergejj.pakus@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Badyan</surname><given-names>K. I.</given-names></name><name xml:lang="ru"><surname>Бадьян</surname><given-names>К. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>344011 Ростов-на-Дону, переулок Доломановский, 70 / 3.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Hasigov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Хасигов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>40 Pushkinskaya St., Vladikavkaz 362019, Republic of North Ossetia.</p></bio><bio xml:lang="ru"><p>Республика Северная Осетия, 362019 Владикавказ, Пушкинская ул., 40.</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Galstyan</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Галстян</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Rostov-on-Don; 70 / 3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>344011 Ростов-на-Дону, переулок Доломановский, 70 / 3.</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Clinical and Diagnostic Center “Zdorovie”</institution></aff><aff><institution xml:lang="ru">Клинико-диагностический центр «Здоровье» г. Ростова-на-Дону</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Department of Radiation Diagnostics with Radiation Therapy and Oncology, North Osetian State Medical Academy, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Кафедра лучевой диагностики с лучевой терапией и онкологией ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2020</year></pub-date><volume>16</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>153</fpage><lpage>164</lpage><history><date date-type="received" iso-8601-date="2019-11-07"><day>07</day><month>11</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2020-07-07"><day>07</day><month>07</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1002">https://oncourology.abvpress.ru/oncur/article/view/1002</self-uri><abstract xml:lang="en"><p>A review of the literature is devoted to the urgent issue of modern oncourology — the treatment of prostate cancer using high-intensity focused ultrasound (HIFU). Currently, there is a trend in shifting the approach from total to focal ablation in patients with prostate cancer of low risk in order to reduce the profile of complications. The article presents the results of modern research on HIFU in both total and focal ablation. Data on oncological, functional results of treatment are given.</p></abstract><trans-abstract xml:lang="ru"><p>Обзор литературы посвящен актуальному вопросу современной онкоурологии — лечению рака предстательной железы с использованием высокоинтенсивного фокусированного ультразвука (HIFU). В настоящее время наблюдается тренд в смещении подхода от тотальной к фокальной аблации у пациентов с раком предстательной железы группы низкого риска в целях снижения профиля осложнений. Приведены результаты современных исследований, посвященных HIFU как в объеме тотальной, так и фокальной аблации. Представлены данные об онкологических, функциональных результатах лечения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>HIFU</kwd><kwd>focal treatment</kwd><kwd>prostate cancer</kwd><kwd>prostate ablation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>HIFU</kwd><kwd>фокальное лечение</kwd><kwd>рак предстательной железы</kwd><kwd>аблация предстательной железы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Alekseev B.Ya., Kaprin A.D., Kolontarev K.B. et al. Prostate cancer. Clinical Recommendations. Russian Society of Urology. Association of Oncologists of Russia. Russian Society of Oncourologists. Russian Society of Clinical Oncology. Moscow, 2018. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Алексеев Б.Я., Каприн А.Д., Колонта-рев К.Б. и др. Рак предстательной железы. Клинические рекомендации. Российское общество урологов. Ассоциация онкологов России. Российское общество онкоурологов. Российское общество клинической онкологии. М., 2018.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu. Urology. Russian Clinical Recommendations. Moscow: GEOTARMedia, 2016. 496 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Российские клинические рекомендации. М.: ГЭОТАР-Медиа, 2016. 496 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Pushkar D.Yu., Govorov A.V., Sidorenkov A.V. et al. Early diagnosis of prostate cancer. Guidelines No. 19. Moscow: ABV-press, 2015. 56 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Пушкарь Д.Ю., Говоров А.В., Сидорен-ков А.В. и др. Ранняя диагностика рака предстательной железы. Методические рекомендации № 19. М.: АБВ-пресс, 2015. 56 c.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">State of oncological care in Russia in 2016. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2017. 236 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2017. 236 с.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Rusakov I.G., Gritskevich A.A. Modern views on the treatment of castrationresistant prostate cancer. Prakticheskaya Oncologiya = Practical Oncology 2012;13(3):156-65. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Русаков И.Г., Грицкевич А.А. Современные представления о лечении каст-рационно-резистентного рака предстательной железы. Практическая онкология 2012;13(3):156-65.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7-30. DOI: 10.3322/caac.21332.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Khmara T.G., Chekhonatskaya M.L., Priezheva V.N. et al. Comparative analysis of clinical, laboratory and radiation diagnostic methods for prostate cancer taking into account the histomorphological gradation of the tumor according to the Gleason score. Byulleten' meditsinskikh internet-konferentsiy = Bulletin of Online Medical Conferences 2014;4(1):68-71. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Хмара Т.Г., Чехонацкая М.Л., Приезже-ва В.Н. и др. Сравнительный анализ данных клинико-лабораторных и лучевых методов диагностики при раке предстательной железы с учетом гистоморфологической градации опухоли по шкале Глисона. Бюллетень медицинских интернет-конференций 2014;4(1):68-71.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Apolikhin O.I., Alekseev B.Ya., Sivkov A.V. et al. Complex radiation and pathomorphological diagnosis of prostate cancer. Ul'trazvukovaya i funkcio-nal'naya diagnostika = Ultrasound and Functional diagnostics 2015;4:18. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Аполихин О.И., Алексеев Б.Я., Сивков А.В. и др. Комплексная лучевая и патоморфологическая диагностика рака предстательной железы. Ультразвуковая и функциональная диагностика 2015;4:18.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Pavlova T.V., Bessmertnyy D.V., Pavlov I.A. Prostate cancer as an interdisciplinary problem (review of literature and own research). Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Meditsina. Farmatsiya = Scientific Reports of Belgorod State University. Series: Medicine. Pharmacy 2012;20(22-2 (141)):93-6. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Павлова Т.В., Бессмертный Д.В., Павлов И.А. Рак предстательной железы как междисциплинарная проблема (обзор литературы и собственных исследований). Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация 2012;20(22-2(141)):93-6.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Moiseev P.I., Yakimovich G.V., Okeanov A.T. et al. Cancer in Europe: a look at the problem, a comparative analysis of some indicators. Onkologicheskiy zhurnal = Oncology Magazine 2014;8(3):13-23. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Моисеев П.И., Якимович Г.В., Океанов А.Т. и др. Рак в Европе: взгляд на проблему, сравнительный анализ некоторых показателей. Онкологический журнал 2014;8(3):13-23.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Petrov S.B., Rakul S.A., Galimov R.D. Treatment of prostate cancer. Prakticheskaya onkologiya = Practical Oncology 2008;9(2):83. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Петров С.Б., Ракул С.А., Галимов Р.Д. Лечение рака предстательной железы. Практическая онкология 2008;9(2):83.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>De Carvalho T.M., Heijnsdiyk E.A., de Koning H.J. Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study. BJU Int 2017;119(4):560-6. DOI: 10.1111/bju.13542.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Klotz L. Active surveillance for prostate cancer: a review. Arch Esp Urol 2011;64(8):806-14.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dalela D., Karabon P., Sammon J. et al. Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) results to contemporary North American men with prostate cancer. Eur Urol 2017;71(4):511-4. DOI: 10.1016/j.eururo.2016.08.048.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Wilt T.J., Brawer M.K., Jones K.M. et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203-13. DOI: 10.1056/NEJMoa1113162.</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Lumpov I.S., Amosov A.V., Krupinov G.E. et al. Focal treatment of patients with prostate cancer with focused high-intensity ultrasound (HIFU). Meditsinskiy vestnik Bashkortostana = Medical Bulletin of Bashkortostan 2015;10(3):157-9. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Лумпов И.С., Амосов А.В., Крупинов Г.Е. и др. Фокальное лечение больных раком предстательной железы фокусированным высокоинтенсивным ультразвуком (HIFU). Медицинский вестник Башкортостана 2015;10(3): 157-9.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Schulman A.A., Polascik T.J. Most of patients with localized prostate cancer will be treated in the future? Opinion: No. Int Braz Urol 2017;43(4):584-7. DOI: 10.1590/S1677-5538.IBJU.2017.04.03.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Stabile A., Dell'Oglio P., De Cobelli F. et al. Association between Prostate Imaging Reporting and Data System (PI-RADS) score for the index lesion and multifocal, clinically significant prostate cancer. Eur Urol Oncol 2018;1(1):29-36. DOI: 10.1016/j.euo.2018.01.002.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Van der Poel H.G., van den Bergh R.C.N., Briers E. et al. Focal therapy in primary localised prostate cancer: The European Association of Urology position in 2018. Eur Urol 2018;74(1):84-91. DOI: 10.1016/j.eururo.2018.01.001.</mixed-citation></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Suleymanov E.A., Filonenko E.V., Moskvicheva L.I. et al. The possibilities of HIFU therapy at the present stage. Issledovaniya i praktika v meditsine = Research and Practical Medicine Journal 2016;3(3): 76-82. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Сулейманов Э.А., Филоненко Е.В., Москвичева Л.И. и др. Возможности HIFU-терапии на современном этапе. Исследования и практика в медицине 2016;3(3):76-82. DOI: 10.17709/2409-2231-2016-3-3-8. In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><mixed-citation>Alkhorayef M., Mahmoud M.Z., Alzimami K.S. et al. High-Intensity Focused Ultrasound (HIFU) in localized prostate cancer treatment. Pol J Radiol 2015;80:131-41. DOI: 10.12659/PJR.892341.</mixed-citation></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Aboyan I.A., Galstyan A.M., Grankina A.O., Maksimov A.Yu. HIFU: prospects of application in oncourology. Politematicheskiy setevoy elektronnyy nauchnyy zhurnal Kubanskogo gosudarstvennogo agrarnogo universiteta = Polythematic Network Electronic Scientific Journal of the Kuban State Agrarian University 2016;(122):264-77. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Абоян И.А., Галстян А.М., Гранкина А.О., Максимов А.Ю. HIFU: перспективы применения в онкоурологии. Полите-матический сетевой электронный на учный журнал Кубанского государственного аграрного университета 2016;(122):264-77.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Aboyan I.A., Badyan K.I., Pakus S.M. et al. Place HIFU in the treatment of prostate cancer. The current state of the problem (literature review). Ural'skiy meditsinskiy zhurnal = Ural Medical Journal 2017;(146):69-74. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Абоян И.А., Бадьян К.И., Пакус С.М. и др. Место HIFU в лечение рака предстательной железы. Современное состояние проблемы (обзор литературы). Уральский медицинский журнал 2017;(146):69-74.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><mixed-citation>Warmuth M., Johansson T., Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Mad Eur Urol 2010;58(6):803-15. DOI: 10.1016/j.eururo.2010.09.009.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Chaussy Ch., Tilki D., Thuroff S. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: current role. J Cancer Ther 2013;4:59-73.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Mc Dannold N., Hynynen K. Quality assurance and system stability of a clinical MRI-guided focused ultrasound system: four-year experience. Med Phys 2006;33(11):4307-13. DOI: 10.1118/1.2352853.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Linke C.A., Carstensen E.L., Frizzell L.A. et al. Localized tissue destruction by high-intensity focused ultrasound. Arch Surg 1973;107(6):887-91. DOI: 10.1001/archsurg.1973.01350240053015.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Bamber J.C., Hill C.R. Ultrasonic attenuation and propagation speed in mammalian tissues as a function of temperature. Ultrasound Med Biol 1979;5(2):149-57. DOI: 10.1016/0301-5629(79)90083-8.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Frizzell L.A. Threshold dosages for damage to mammalian liver by high intensity focused ultrasound. IEEE Trans Ultrason Ferroelectr Freq Control 1988;35(5):578-81. DOI: 10.1109/58.8036.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Goss S., Fry F. The effect of high intensity ultrasonic irradiation on tumor growth. IEEE Trans. Sonics Ultrason 1984; SU-31(5):491-6.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ma C.M., Chen X., Cvetkovic D., Chen L. An in-vivo investigation of the therapeutic effect of pulsed focused ultrasound on tumor growth. Med Phys 2014;41(12):122901. DOI: 10.1118/1.4901352.</mixed-citation></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Aboyan I.A., Badyan K.I., Grachev S.V. et al. Prostate cancer: topical staging and prediction issues. Zhurnal fundamental'noy meditsiny i biologii = Journal of Basic Medicine and Biology 2016;(3):51-5. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Абоян И.А., Бадьян К.И., Грачев С.В. и др. Рак предстательной железы: актуальные вопросы стадирования и прогнозирования. Журнал фундаментальной медицины и биологии 2016;(3):51-5.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><mixed-citation>Marshall S., Taneja S. Focal therapy for prostate cancer: the current status. Prostate Int 2015;3(2):35-41. DOI: 10.1016/j.prnil.2015.03.007.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Barnett S.B., ter Haar G.R., Ziskin M.C. et al. Current status of research on biophysical effects of ultrasound. Ultrasound Med Biol 1994;20(3):205-18. DOI: 10.1016/0301-5629(94)90060-4.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Curiel L., Chavrier F., Gignoux B. et al. Experimental evaluation of lesion prediction modelling in the presence of cavitation bubbles: intended for high-intensity focused ultrasound prostate treatment. Med Biol Eng Comput 2004;42(1):44-54. DOI: 10.1007/BF02351010.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Eggener S.E., Scardino P.T., Carroll P.R. et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Urology 2007;178(6):2260-7. DOI: 10.1016/j.juro.2008.04.045.</mixed-citation></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Aboyan I.A., Galstyan A.M., Badyan K.I., Pakus S.M. HIFU hemiablation in patients with localized forms of prostate cancer. Eksperimental'naya i klinicheskaya urologiya = Experimental and Clinical Urology 2018;(1):42-6. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Абоян И.А., Галстян А.М., Бадьян К.И., Пакус С.М. HIFU-гемиаблация у пациентов с локализованными формами рака предстательной железы. Экспериментальная и клиническая урология 2018;(1):42-6. DOI: 10.29188/2222-8543-2018-9-1.</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><mixed-citation>Madersbacher S., Pedevilla M., Vingers L. et al. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995;55(15):3346-51.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Chapelon J.Y., Ribault M., Vernier F. et al. Treatment of localised prostate cancer with transrectal high intensity focused ultrasound. Eur J Ultrasound 1999;9(1):31-8. DOI: 10.1016/s0929-8266(99)00005-1.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Chaussy C.G., Thuroff S. High-intensity focused ultrasound for the treatment of prostate cancer: a review. J Endourology 2017;31(S1):S30-7. DOI: 10.1089/end.2016.0548.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Crouzet S., Rouviere O., Martin X., Gelet A. High-intensity focused ultrasound as focal therapy of prostate cancer. Curr Opin Urology 2014;24(3):225-30. DOI: 10.1016/s0929-8266(99)00005-1.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Chapelon J.Y., Rouviere O., Crouzet S., Gelet A. Prostate Focused Ultrasound Therapy. Adv Exp Med Biol 2016;880:21-41. DOI: 10.1007/978-3-319-22536-4_2.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Ganzer R., Franiel T., Kollermann J. et al. Focal therapy of prostate cancer. Urology A 2017;56(10):1335-46. DOI: 10.1007/s00120-017-0488-z.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Sundaram K.M., Chang S.S., Penson D.F., Arora S. Therapeutic ultrasound and prostate cancer. Semin Int Radiol 2017;34(2):187-200. DOI: 10.1055/s-0037-1602710.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Veereman G., Jonckheer P., Desomer A. et al. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for localised prostate cancer. Eur Urol Focus 2015;1(2):158-70. DOI: 10.1016/j.euf.2015.04.006.</mixed-citation></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Solovov V.A., Orlov A.E., Vozdvizhenskiy M.O. et al. High-intensity focused ultrasound ablation (HIFU) of prostate cancer in 976 patients: 7-year results. Izvestiya Samarskogo nauchnogo tsentra RAN = Bulletin of the Samara Scientific Center of the Russian Academy of Sciences 2015;17(2-3):682-5. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Соловов В.А., Орлов А.Е., Воздвиженский М.О. и др. Высокоинтенсивная фокусированная ультразвуковая аблация (HIFU) рака предстательной железы у 976 пациентов: 7-летние результаты. Известия Самарского научного центра РАН 2015;17(2-3):682-5.</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Gubanov E.S., Boryaev E.A., Zimichev A.A. Urological complications of HIFU-therapy of prostate cancer: international and domestic experience. Samarskiy gosudarstvennyy meditsinskiy universitet = Samara State Medical University 2016;(1-2):133-8. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Губанов Е.С., Боряев Е.А., Зимичев А.А. Урологические осложнения HIFU-терапии рака предстательной железы: мировой и отечественный опыт. Самарский государственный медицинский университет 2016;(1-2): 133-8.</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">Alyaev Yu.G., Krupinov G.E., Grigoryan V.A. et al. High-intensity focused ultrasound in the treatment of prostate cancer. Onkourologiya = Cancer Urology 2007;(2):34-41. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Аляев Ю.Г., Крупинов Г.Е., Григорян В.А. и др. Высокоинтенсивный фокусированный ультразвук в лечении рака предстательной железы. Онкоурология 2007;(2):34-41.</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Glybochko P.V., Fomkin R.N., Ponukalin A.N. et al. First experience with high intensity focused ultrasound ablation (HIFU) in the treatment of prostate cancer. Saratovskiy nauchno-medicinskii zhurnal = Saratov Journal of Medical Scientific Research 2009;5(4):599-603. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Глыбочко П.В., Фомкин Р.Н., Понука-лин А.Н. и др. Первый опыт применения высокоинтенсивной фокусированной ультразвуковой аблации (HIFU) в лечении рака простаты. Саратовский научно-медицинский журнал 2009;5(4):599-603.</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><mixed-citation>Dickinson L., Arya M., Afzal N. et al. Medium-term outcomes after whole-gland high-intensity focused ultrasound for the treatment of nonmetastatic prostate cancer from a multicentre registry cohort. Eur Urol 2016;70(4):668-74. DOI: 10.1016/j.eururo.2016.02.054.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Ramsay C.R., Adewuyi T.E., Gray J. et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19(49):1-490. DOI: 10.3310/hta19490.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Pfeiffer D., Berger J., Gross A. Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: treatment-related predictors of biochemical outcomes. Asian J Urology 2015;2(1):46-52. DOI: 10.1016/j.ajur.2014.08.009.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Chen P.Y., Chiang P.H., Liu Y.Y. et al. Primary whole gland ablation for localized prostate cancer with high-intensity focused ultrasound: the important predictors of biochemical recurrence. Int J Urology 2018;25(6):615-20. DOI: 10.1111/iju.13581.</mixed-citation></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Krupinov G.E. Treatment of patients with prostate cancer with high-intensity focused ultrasound. Dis. ... doctor of medical sciences: 14.01.23. Moscow, 2010. 246 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Крупинов Г.Е. Лечение больных раком предстательной железы высокоинтенсивным фокусированным ультразвуком. Дис. ... д-ра мед. наук: 14.01.23. М., 2010. 246 с.</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">Badyan K.I. Modern approaches to predicting the risk of recurrence of prostate cancer after HIFU. Abstract of thesis of the candidate of medical sciences, 2018. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Бадьян К.И. Современные подходы к прогнозированию риска развития рецидива рака предстательной железы после HIFU. Автореф. дис. ... канд. мед. наук, 2018.</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">Imankulov S.B., Zhampeyisov N.K., Oskenbaeva K.K. Ultrasound ablation (HIFU therapy) in the treatment of kidney cancer. Klinicheskaya meditsina Kazahstana = Clinical Medicine of Kazakhstan 2014;1(31):91-2. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Иманкулов С.Б., Жампеисов Н.К., Оскенбаева К.К. Ультразвуковая аблация (HIFU терапия) в лечении рака почки. Клиническая медицина Казахстана 2014;1(31):91-2.</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">Fomkin R.N., Shatylko T.V. Nadir PSA as the main predictor of relapse of localized prostate cancer after HIFU ablation. Urology 2016;(5):489-96. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Фомкин Р.Н., Шатылко Т.В. Надир ПСА как основной предиктор рецидива локализованного рака простаты после HIFU-аблации. Урология 2016;(5):489-96. DOI: 10.18484/23050047.2016.5.489.</mixed-citation></citation-alternatives></ref><ref id="B58"><label>58.</label><citation-alternatives><mixed-citation xml:lang="en">Guliyev F.A. Predictors of biochemical progression of prostate cancer. Kazanskiy medicinskiy zhurnal = Kazan Medical 2017;98(6):890-4. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Гулиев Ф.А. Предикторы биохимического прогрессирования рака предстательной железы. Казанский медицинский журнал 2017;98(6):890-4.</mixed-citation></citation-alternatives></ref><ref id="B59"><label>59.</label><mixed-citation>Ganzer R., Fritsche H.M., Brandtner A. et al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 2013;112(3):322-9. DOI: 10.1111/j.1464-410X.2012.11715.x.</mixed-citation></ref><ref id="B60"><label>60.</label><citation-alternatives><mixed-citation xml:lang="en">Neymark A.I., Tachalov M.A., Neymark B.A. Features of HIFU (high intensity focfused ultrasound)-therapy in the treatment of localized prostate cancer. Meditsina i obrazovanie v Sibiri = Journal of Siberian Medical Sciences 2013;(5):17. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Неймарк А.И., Тачалов М.А., Неймарк Б.А. Возможности HIFU (high intensity focfused и1йжоиЫ)-тера-пии в лечении локализованного рака предстательной железы. Медицина и образование в Сибири 2013;(5):17.</mixed-citation></citation-alternatives></ref><ref id="B61"><label>61.</label><citation-alternatives><mixed-citation xml:lang="en">Popkov V.M., Fomkin R.N., Blumberg B.I. Prognostic factors in evaluating the effectiveness of treatment results for patients with localized prostate cancer using HIFU ablation. Saratovskiy nauchno-meditsinskiy zhurnal = Saratov Journal of Medical Scientific Research 2013;9(1):116-21. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Попков В.М., Фомкин Р.Н., Блюмберг Б.И. Прогностические факторы в оценке эффективности результатов лечения больных локализованным раком простаты с помощью HIFU-аблации. Саратовский научномедицинский журнал 2013;9(1):116-21.</mixed-citation></citation-alternatives></ref><ref id="B62"><label>62.</label><mixed-citation>Edison E., Tariq Shah T., Ahmed H.U. Focal ablation of early-stage prostate cancer: candidate selection, treatment guidance, and assessment of outcome. Urol Clin North Am 2017;44(4):575-85. DOI: 10.1016/j.ucl.2017.07.006.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Bostwick D.G., Waters D.J., Farley E.R. et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007;70(6 Suppl):42-4. DOI: 10.1016/j.urology.2007.07.037.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>De la Rosette J., Ahmed H., Barentsz J. et al. Focal therapy in prostate cancerreport from a consensus panel. J Endourol 2010;24(5):775-80. DOI: 10.1089/end.2009.0596.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Ahmed H.U., Akin O., Coleman J.A. et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2012;109(11):1636-47. DOI: 10.1111/j.1464-410X.2011.10633.x.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Langley S., Ahmed H.U., Al-Qaisieh B. et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 2012;109 (Suppl 1):7-16. DOI: 10.1111/j.1464-410X.2011.10825.x.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Donaldson I.A., Alonzi R., Barratt D. et al. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol 2015;67(4):771-7. DOI: 10.1016/j.eururo.2014.09.018.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Tay K.J., Schulman A.A., Sze C. et al. New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther 2017;17(8):737-43. DOI: 10.1080/14737140.2017.1345630.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Polascik T.J., Mayes J.M., Schroeck F.R. et al. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer 2009;115(10):2104-10. DOI: 10.1002/cncr.24258.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Tsivian M., Moreira D.M., Sun L. et al. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urol Oncol 2012;30(1):21-5. DOI: 10.1016/j.urolonc.2009.11.001.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Mayes J.M., Mouraviev V., Sun L. et al. Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol 2011;29(2):166-70. DOI: 10.1016/j.urolonc.2009.03.011.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Gallina A., Maccagnano C., Suardi N. et al. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU Int 2012;110(2 Pt 2):E64-8. DOI: 10.1111/j.1464-410X.2011.10762.x.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Katz B., Srougi M., Camara-Lopes L.H. et al. The accuracy of pathological data for the prediction of insignificant prostate cancer. Int. Braz J Urol 2012;38(6):760-8. DOI: 10.1590/1677-553820133806760.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Sinnott M., Falzarano S.M., Hernandez A.V. et al. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy. Prostate 2012;72(11):1179-86. DOI: 10.1002/pros.22467.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Washington S.L., Bonham M., Whitson J.M. et al. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int 2012;110(1):50-5. DOI: 0.1111/j.1464-410X.2011.10704.x.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Berg K.D., Toft B.G., R0der MA et al. Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies? APMIS 2013;121(4):257-65. DOI: 10.1111/j.1600-0463.2012.02965.x.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Onik G., Miessau M., Bostwick D.G. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009;27(26):4321-6. DOI: 10.1200/JCO.2008.20.3497.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Ahmed H.U., Hu Y., Carter T. et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011;186(2):458-64. DOI: 10.1016/j.juro.2011.03.147.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Barqawi A.B., Rove K.O., Gholizadeh S. et al. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol 2011;186(1):80-5. DOI: 10.1016/j.juro.2011.03.005.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Hossack T., Patel M.I., Huo A. et al. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. J Urol 2012;188(3):781-5. DOI: 10.1016/j.juro.2012.05.006.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Huo A.S., Hossack T., Symons J.L. et al. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. J Urol 2012;187(6):2044-9. DOI: 10.1016/j.juro.2012.01.066.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Hu Y., Ahmed H.U., Carter T. et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int 2012;110(6):812-20. DOI: 10.1111/j.1464-410X.2012.10933.x.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Long J.A., Hungr N., Baumann M. et al. Development of a novel robot for transperineal needle-based interventions: focal therapy, brachytherapy and prostate biopsies. J Urol 2012;188(4):1369-74. DOI: 10.1016/j.juro.2012.06.003.</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Crawford E.D., Rove K.O., Barqawi A.B. et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 2013;73(7):778-87. DOI: 10.1002/pros.22622.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Losa A., Gadda G.M., Lazzeri M. et al. Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy. Urology 2013;81(6):1291-6. DOI: 10.1016/j.urology.2012.11.078.</mixed-citation></ref><ref id="B86"><label>86.</label><citation-alternatives><mixed-citation xml:lang="en">Glybochko P.V., Voskanyan G.A., Vinarov A.Z. et al. Visualization of prostate cancer using magnetic resonance spectroscopy. Meditsinskiy vestnik Bashkortostana = Medical Bulletin of Bashkortostan 2013;8(2):241-5. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Глыбочко П.В., Восканян Г.А., Винаров А.З. и др. Визуализация рака предстательной железы с использованием магниторезонансной спектроскопии. Медицинский вестник Башкортостана 2013;8(2):241-5.</mixed-citation></citation-alternatives></ref><ref id="B87"><label>87.</label><citation-alternatives><mixed-citation xml:lang="en">Sadchenko A.V., Govorov A.V., Pushkar D.Yu., Vasiliev A.O. Saturation biopsy of the prostate gland (literature review). Onkourologiya = Cancer Urology 2013;9(3):70-5. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Садченко А.В., Говоров А.В., Пушкарь Д.Ю., Васильев А.О. Сатурационная биопсия предстательной железы (обзор литературы). Онкоурология 2013;9(3):70-5.</mixed-citation></citation-alternatives></ref><ref id="B88"><label>88.</label><citation-alternatives><mixed-citation xml:lang="en">Korobkin A.S., Sharia M.A., Voskanyan G.A., Vinarov A.Z. Multiparameter magnetic resonance imaging in the diagnosis of prostate cancer. Andrology and Genital Surgery 2015;16(1):53-61. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Коробкин А.С., Шария М.А., Восканян Г.А., Винаров А.З. Мультипараметрическая магнитнорезонансная томография в диагностике рака предстательной железы. Андрология и генитальная хирургия 2015;16(1):53-61. DOI: 10.17650/2070-9781-2015-1-53-61.</mixed-citation></citation-alternatives></ref><ref id="B89"><label>89.</label><mixed-citation>Muto S., Yoshii T., Saito K. et al. Focal therapy with high-intensity-focused ultrasound in the treatment localized prostate cancer. Jpn J Clin Oncol 2008;38(3):192-9. DOI: 10.1093/jjco/hym173.</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Van Velthoven R., Aoun F., Marcelis Q. et al. A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2016;19(1):79-83. DOI: 10.1038/pcan.2015.55.</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Albisinni S., Aoun F., Bellucci S. et al. Comparing high intensity focal ultrasound hemiablation to robotic radical prostatectomy in the management of unilateral prostate cancer: a matched-pair analysis. J Endourology 2017;31(1):14-9. DOI: 10.1089/end.2016.0702.</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Fegoun A.B., Barret E., Prapotnich D. et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol 2011;37(2):213-9; discussion 220-2. DOI: 10.1590/s1677-55382011000200008.</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Ahmed H.U., Freeman A., Kirkham A. et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011;185(4):1246-54. DOI: 10.1016/j.juro.2010.11.079.</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Coleman J.A. Functional outcomes of partial prostate ablation and focal therapy: are we managing expectations of a bar set too high. Curr Opin Urology 2015;25(3):220-4. DOI: 10.1097/MOU.0000000000000169.</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Ahmed H.U., Dickinson L., Charman S. et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 2015;68(6):927-36. DOI: 10.1016/j.eururo.2015.01.030.</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Feijoo E.R., Sivaraman A., Barret E. et al. Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes. Eur Urol 2016;69(2):214-20. DOI: 10.1016/j.eururo.2015.06.018.</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Ganzer R., Hadaschik B., Pahernik S. et al. Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound. J Urol 2018;199(4):983-9. DOI: 10.1016/j.juro.2017.10.033.</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>Rischmann P., Gelet A., Riche B. et al. Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol 2017;71(2):267-73. DOI: 10.1016/j.eururo.2016.09.039.</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Albisinni S., Melot C., Aoun F. et al. Focal treatment for unilateral prostate cancer using HIFU: a comprehensive study of pooled data. J Endourol 2018;32(9):797-804. DOI: 10.1089/end.2018.0130.</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation>Walker Faure N.A., Norris J.M., Shah T.T. et al. A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: a systematic review. Urol Oncol 2018;36(2):67-7. DOI: 10.1016/j.urolonc.2017.12.002.</mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation>Golan R., Bernstein A.N., McClure T.D. et al. Partial gland treatment of prostate cancer using high-intensity focused ultrasound in the primary and salvage settings: a systematic review. J Urol 2017;198(5):1000-9. DOI: 10.1016/j.juro.2017.03.137.</mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation>Guillaumier S., Peters M., Arya M. et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol 2018;74(4): 422-9. DOI: 10.1016/j.eururo.2018.06.006.</mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation>Stabile A., Orczyk C., Hosking-Jervis F. et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int 2019;124(3):431-40. DOI: 10.1111/bju.14710.</mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation>Lebastchi A.H., George A.K., Polascik T.J. et al. Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus. Eur Urol 2020. DOI: 10.1016/j.eururo.2020.05.018.</mixed-citation></ref></ref-list></back></article>
